|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Heidenreich A, Bastian PJ, Bellmunt J,
Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T,
Zattoni F, et al: EAU guidelines on prostate cancer. Part II:
Treatment of advanced, relapsing, and castration-resistant prostate
cancer. Eur Urol. 65:467–479. 2014. View Article : Google Scholar
|
|
3
|
Mottet N, Bellmunt J, Bolla M, Briers E,
Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau
S, et al: EAU-ESTRO-SIOG Guidelines on prostate cancer. Part 1:
Screening, diagnosis, and local treatment with curative intent. Eur
Urol. 71:618–629. 2017. View Article : Google Scholar
|
|
4
|
Bill-Axelson A, Holmberg L, Garmo H, Rider
JR, Taari K, Busch C, Nordling S, Häggman M, Andersson SO,
Spångberg A, et al: Radical prostatectomy or watchful waiting in
early prostate cancer. N Engl J Med. 370:932–942. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hayes JH, Ollendorf DA, Pearson SD, Barry
MJ, Kantoff PW, Lee PA and McMahon PM: Observation versus initial
treatment for men with localized, low-risk prostate cancer: A
cost-effectiveness analysis. Ann Intern Med. 158:853–860. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Godtman RA, Holmberg E, Khatami A, Stranne
J and Hugosson J: Outcome following active surveillance of men with
screen-detected prostate cancer. Results from the Göteborg
randomised population-based prostate cancer screening trial. Eur
Urol. 63:101–107. 2013. View Article : Google Scholar
|
|
7
|
Cornford P, Bellmunt J, Bolla M, Briers E,
De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, et al:
EAU-ESTRO-SIOG Guidelines on prostate cancer. Part II: Treatment of
relapsing, metastatic, and castration-resistant prostate cancer.
Eur Urol. 71:630–642. 2017. View Article : Google Scholar
|
|
8
|
Zaorsky NG, Raj GV, Trabulsi EJ, Lin J and
Den RB: The dilemma of a rising prostate-specific antigen level
after local therapy: What are our options? Semin Oncol. 40:322–336.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Roehl KA, Han M, Ramos CG, Antenor JA and
Catalona WJ: Cancer progression and survival rates following
anatomical radical retropubic prostatectomy in 3,478 consecutive
patients: Long-term results. J Urol. 172:910–914. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Freedland SJ, Humphreys EB, Mangold LA,
Eisenberger M, Dorey FJ, Walsh PC and Partin AW: Risk of prostate
cancer-specific mortality following biochemical recurrence after
radical prostatectomy. JAMA. 294:433–439. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kupelian PA, Mahadevan A, Reddy CA,
Reuther AM and Klein EA: Use of different definitions of
biochemical failure after external beam radiotherapy changes
conclusions about relative treatment efficacy for localized
prostate cancer. Urology. 68:593–598. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Artibani W, Porcaro AB, De Marco V,
Cerruto MA and Siracusano S: Management of biochemical recurrence
after primary curative treatment for prostate cancer: A review.
Urol Int. 100:251–262. 2018. View Article : Google Scholar
|
|
13
|
Pound CR, Partin AW, Eisenberger MA, Chan
DW, Pearson JD and Walsh PC: Natural history of progression after
PSA elevation following radical prostatectomy. JAMA. 281:1591–1597.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Boorjian SA, Thompson RH, Tollefson MK,
Rangel LJ, Bergstralh EJ, Blute ML and Karnes RJ: Long-term risk of
clinical progression after biochemical recurrence following radical
prostatectomy: The impact of time from surgery to recurrence. Eur
Urol. 59:893–899. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Heinlein CA and Chang C: Androgen receptor
in prostate cancer. Endoc Rev. 25:276–308. 2004. View Article : Google Scholar
|
|
16
|
Tannock IF, de Wit R, Berry WR, Horti J,
Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et
al: Docetaxel plus prednisone or mitoxantrone plus prednisone for
advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Berthold DR, Pond GR, Soban F, de Wit R,
Eisenberger M and Tannock IF: Docetaxel plus prednisone or
mitoxantrone plus prednisone for advanced prostate cancer: Updated
survival in the TAX 327 study. J Clin Oncol. 26:242–245. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
de Bono JS, Logothetis CJ, Molina A,
Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F,
et al: Abiraterone and increased survival in metastatic prostate
cancer. N Engl J Med. 364:1995–2005. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Scher HI, Fizazi K, Saad F, Taplin ME,
Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et
al: Increased survival with enzalutamide in prostate cancer after
chemotherapy. N Engl J Med. 367:1187–1197. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cooperberg MR, Pasta DJ, Elkin EP, Litwin
MS, Latini DM, Du Chane J and Carroll PR: The University of
California, San Francisco Cancer of the Prostate Risk Assessment
score: A straightforward and reliable preoperative predictor of
disease recurrence after radical prostatectomy. J Urol.
173:1938–1942. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Brajtbord JS, Leapman MS and Cooperberg
MR: The CAPRA Score at 10 Years: Contemporary perspectives and
analysis of supporting studies. Eur Urol. 71:705–709. 2017.
View Article : Google Scholar
|
|
22
|
Cooperberg MR, Hilton JF and Carroll PR:
The CAPRA-S score: A straightforward tool for improved prediction
of outcomes after radical prostatectomy. Cancer. 117:5039–5046.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
D'Amico AV, Whittington R, Malkowicz SB,
Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA,
Kaplan I, Beard CJ and Wein A: Biochemical outcome after radical
prosta-tectomy, external beam radiation therapy, or interstitial
radiation therapy for clinically localized prostate cancer. JAMA.
280:969–974. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dillioglugil O, Leibman BD, Kattan MW,
Seale-Hawkins C, Wheeler TM and Scardino PT: Hazard rates for
progression after radical prostatectomy for clinically localized
prostate cancer. Urology. 50:93–99. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Han M, Partin AW, Zahurak M, Piantadosi S,
Epstein JI and Walsh PC: Biochemical (prostate specific antigen)
recurrence probability following radical prostatectomy for
clinically localized prostate cancer. J Urol. 169:517–523. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Simmons MN, Stephenson AJ and Klein EA:
Natural history of biochemical recurrence after radical
prostatectomy: Risk assessment for secondary therapy. Eur Urol.
51:1175–1184. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lange PH, Ercole CJ, Lightner DJ, Fraley
EE and Vessella R: The value of serum prostate specific antigen
determinations before and after radical prostatectomy. J Urol.
141:873–879. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim DK, Koo KC, Lee KS, Hah YS, Rha KH,
Hong SJ and Chung BH: Time to disease recurrence is a predictor of
metastasis and mortality in patients with High-risk prostate cancer
who achieved undetectable prostate-specific antigen following
Robot-assisted radical prostatectomy. J Korean Med Sci.
33:e2852018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Walz J, Chun FK, Klein EA, Reuther A, Saad
F, Graefen M, Huland H and Karakiewicz PI: Nomogram predicting the
probability of early recurrence after radical prostatectomy for
prostate cancer. J Urol. 181:601–608. 2009. View Article : Google Scholar
|
|
30
|
Pompe RS, Bandini M, Preisser F, Marchioni
M, Zaffuto E, Tian Z, Salomon G, Schlomm T, Huland H, Graefen M, et
al: Contemporary approach to predict early biochemical recurrence
after radical prostatectomy: Update of the Walz nomogram. Prostate
Cancer Prostatic Dis. 21:386–393. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sherr CJ: Cancer cell cycles. Science.
274:1672–1677. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ross AE, D'Amico AV and Freedland SJ:
Which, when and why? Rational use of tissue-based molecular testing
in local-ized prostate cancer. Prostate Cancer Prostatic Dis.
19:1–6. 2016. View Article : Google Scholar
|
|
33
|
Carneiro A, Barbosa ARG, Takemura LS,
Kayano PP, Moran NKS, Chen CK, Wroclawski ML, Lemos GC, da Cunha
IW, Obara MT, et al: The role of immunohistochemical analysis as a
tool for the diagnosis, prognostic evaluation and treatment of
prostate cancer: A systematic review of the literature. Front
Oncol. 8:3772018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Iatropoulos MJ and Williams GM:
Proliferation markers. Exp Toxicol Pathol. 48:175–181. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fantony JJ, Howard LE, Csizmadi I,
Armstrong AJ, Lark AL, Galet C, Aronson WJ and Freedland SJ: Is
Ki67 prognostic for aggressive prostate cancer? A multicenter
real-world study. Biomark Med. 12:727–736. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wong N, Ojo D, Yan J and Tang D: PKM2
contributes to cancer metabolism. Cancer Lett. 356:184–191. 2015.
View Article : Google Scholar
|
|
37
|
Carabet LA, Rennie PS and Cherkasov A:
Therapeutic inhibition of myc in cancer. Structural bases and
computer-aided drug discovery approaches. Int J Mol Sci. 20:pii:
E120. 2018. View Article : Google Scholar
|
|
38
|
Gurel B, Iwata T, Koh CM, Jenkins RB, Lan
F, Van Dang C, Hicks JL, Morgan J, Cornish TC, Sutcliffe S, et al:
Nuclear MYC protein overexpression is an early alteration in human
prostate carcinogenesis. Mod Pathol. 21:1156–1167. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Baena-Del Valle JA, Zheng Q, Esopi DM,
Rubenstein M, Hubbard GK, Moncaliano MC, Hruszkewycz A, Vaghasia A,
Yegnasubramanian S, Wheelan SJ, et al: MYC drives overex-pression
of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol.
244:11–24. 2018. View Article : Google Scholar
|
|
40
|
Hubbard GK, Mutton LN, Khalili M, McMullin
RP, Hicks JL, Bianchi-Frias D, Horn LA, Kulac I, Moubarek MS,
Nelson PS, et al: Combined MYC activation and pten loss are
sufficient to create genomic instability and lethal metastatic
prostate cancer. Cancer Res. 76:283–292. 2016. View Article : Google Scholar :
|
|
41
|
Tomlins SA, Rhodes DR, Perner S,
Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J,
Kuefer R, et al: Recurrent fusion of TMPRSS2 and ETS transcription
factor genes in prostate cancer. Science. 310:644–648. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Park K, Tomlins SA, Mudaliar KM, Chiu YL,
Esgueva R, Mehra R, Suleman K, Varambally S, Brenner JC, MacDonald
T, et al: Antibody-based detection of ERG rearrangement-positive
prostate cancer. Neoplasia. 12:590–598. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Inoue T, Segawa T, Shiraishi T, Yoshida T,
Toda Y, Yamada T, Kinukawa N, Kinoshita H, Kamoto T and Ogawa O:
Androgen receptor, Ki67, and p53 expression in radical
prostatectomy specimens predict treatment failure in Japanese
population. Urology. 66:332–337. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Osman I, Drobnjak M, Fazzari M, Ferrara J,
Scher HI and Cordon-Cardo C: Inactivation of the p53 pathway in
prostate cancer: Impact on tumor progression. Clin Cancer.
5:2082–2088. 1999.
|
|
45
|
Hemminki K: Familial risk and familial
survival in prostate cancer. World J Urol. 30:143–148. 2012.
View Article : Google Scholar
|
|
46
|
Castro E, Goh C, Olmos D, Saunders E,
Leongamornlert D, Tymrakiewicz M, Mahmud N, Dadaev T, Govindasami
K, Guy M, et al: Germline BRCA mutations are associated with higher
risk of nodal involvement, distant metastasis, and poor survival
outcomes in prostate cancer. J Clin Oncol. 31:1748–1757. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Castro E, Goh C, Leongamornlert D,
Saunders E, Tymrakiewicz M, Dadaev T, Govindasami K, Guy M, Ellis
S, Frost D, et al: Effect of BRCA mutations on metastatic relapse
and Cause-specific survival after radical treatment for localised
prostate cancer. Eur Urol. 68:186–193. 2015. View Article : Google Scholar
|
|
48
|
Taylor RA, Fraser M, Livingstone J,
Espiritu SM, Thorne H, Huang V, Lo W, Shiah YJ, Yamaguchi TN,
Sliwinski A, et al: Germline BRCA2 mutations drive prostate cancers
with distinct evolutionary trajectories. Nat Commun. 8:136712017.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Pritchard CC, Mateo J, Walsh MF, De Sarkar
N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R,
et al: Inherited DNA-repair gene mutations in men with metastatic
prostate cancer. N Engl J Med. 375:443–453. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cooperberg MR, Erho N, Chan JM, Feng FY,
Fishbane N, Zhao SG, Simko JP, Cowan JE, Lehrer J, Alshalalfa M, et
al: The diverse genomic landscape of clinically Low-risk prostate
cancer. Eur Urol. 74:444–452. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Curtis C, Shah SP, Chin SF, Turashvili G,
Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et
al: The genomic and transcriptomic architecture of 2,000 breast
tumours reveals novel subgroups. Nature. 486:346–352. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Evans JR, Zhao SG, Chang SL, Tomlins SA,
Erho N, Sboner A, Schiewer MJ, Spratt DE, Kothari V, Klein EA, et
al: Patient-level DNA damage and repair pathway profiles and
prognosis after prostatectomy for high-risk prostate cancer. JAMA
Oncol. 2:471–480. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Magi-Galluzzi C, Tsusuki T, Elson P,
Simmerman K, LaFargue C, Esgueva R, Klein E, Rubin MA and Zhou M:
TMPRSS2-ERG gene fusion prevalence and class are significantly
different in prostate cancer of Caucasian, African-American and
Japanese patients. Prostate. 71:489–497. 2011. View Article : Google Scholar
|
|
54
|
Ren S, Peng Z, Mao JH, Yu Y, Yin C, Gao X,
Cui Z, Zhang J, Yi K, Xu W, et al: RNA-seq analysis of prostate
cancer in the Chinese population identifies recurrent gene fusions,
cancer-associated long noncoding RNAs and aberrant alternative
splicings. Cell Res. 22:806–821. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Song C and Chen H: Predictive significance
of TMRPSS2-ERG fusion in prostate cancer: A meta-analysis. Cancer
Cell Int. 18:1772018. View Article : Google Scholar :
|
|
56
|
Shamseer L, Moher D, Clarke M, Ghersi D,
Liberati A, Petticrew M, Shekelle P and Stewart LA; PRISMA-P Group:
Preferred reporting items for systematic review and meta-analysis
protocols (PRISMA-P) 2015: Elaboration and explanation. BMJ.
350:g76472015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Moher D, Shamseer L, Clarke M, Ghersi D,
Liberati A, Petticrew M, Shekelle P and Stewart LA; PRISMA-P Group:
Preferred reporting items for systematic review and meta-analysis
protocols (PRISMA-P) 2015 statement. Syst Rev. 4:12015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Nam RK, Benatar T, Wallis CJ, Amemiya Y,
Yang W, Garbens A, Naeim M, Sherman C, Sugar L and Seth A: MiR-301a
regulates E-cadherin expression and is predictive of prostate
cancer recurrence. Prostate. 76:869–884. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Li T, Li RS, Li YH, Zhong S, Chen YY,
Zhang CM, Hu MM and Shen ZJ: miR-21 as an independent biochemical
recurrence predictor and potential therapeutic target for prostate
cancer. J Urol. 187:1466–1472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Sun X, Yang Z, Zhang Y, He J, Wang F, Su
P, Han J, Song Z and Fei Y: Prognostic implications of tissue and
serum levels of microRNA-128 in human prostate cancer. Int J Clin
Exp Pathol. 8:8394–8401. 2015.PubMed/NCBI
|
|
61
|
Aakula A, Kohonen P, Leivonen SK, Mäkelä
R, Hintsanen P, Mpindi JP, Martens-Uzunova E, Aittokallio T,
Jenster G, Perälä M, et al: Systematic identification of MicroRNAs
that impact on proliferation of prostate cancer cells and display
changed expression in tumor tissue. Eur Urol. 69:1120–1128. 2016.
View Article : Google Scholar
|
|
62
|
Ling XH, Han ZD, Xia D, He HC, Jiang FN,
Lin ZY, Fu X, Deng YH, Dai QS, Cai C, et al: MicroRNA-30c serves as
an independent biochemical recurrence predictor and potential tumor
suppressor for prostate cancer. Mol Biol Rep. 41:2779–2788. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Avgeris M, Stravodimos K, Fragoulis EG and
Scorilas A: The loss of the tumour-suppressor miR-145 results in
the shorter disease-free survival of prostate cancer patients. Br J
Cancer. 108:2573–2581. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Tao Z, Xu S, Ruan H, Wang T, Song W, Qian
L and Chen K: MiR-195/-16 family enhances radiotherapy via T cell
activation in the tumor microenvironment by blocking the PD-L1
immune checkpoint. Cell Physiol Biochem. 48:801–814. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Shibue T and Weinberg RA: EMT, CSCs, and
drug resistance: The mechanistic link and clinical implications.
Nat Rev Clin Oncol. 14:611–629. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Mei W, Lin X, Kapoor A, Gu Y, Zhao K and
Tang D: The contributions of prostate cancer stem cells in prostate
cancer initiation and metastasis. Cancers (Basel). 11:pii: E434.
2019. View Article : Google Scholar
|
|
67
|
Yang Y, Guo JX and Shao ZQ: miR-21 targets
and inhibits tumor suppressor gene PTEN to promote prostate cancer
cell proliferation and invasion: An experimental study. Asian Pac J
Trop Med. 10:87–91. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zhao Y, Yin Z, Li H, Fan J, Yang S, Chen C
and Wang DW: MiR-30c protects diabetic nephropathy by suppressing
epithelial-to-mesenchymal transition in db/db mice. Aging Cell.
16:387–400. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zhu C, Hou X, Zhu J, Jiang C and Wei W:
Expression of miR-30c and miR-29b in prostate cancer and its
diagnostic significance. Oncol Lett. 16:3140–3144. 2018.PubMed/NCBI
|
|
70
|
Sachdeva M, Liu Q, Cao J, Lu Z and Mo YY:
Negative regulation of miR-145 by C/EBP-β through the Akt pathway
in cancer cells. Nucleic Acids Res. 40:6683–6692. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Ozen M, Creighton CJ, Ozdemir M and
Ittmann M: Widespread deregulation of microRNA expression in human
prostate cancer. Oncogene. 27:1788–1793. 2008. View Article : Google Scholar
|
|
72
|
Wach S, Nolte E, Szczyrba J, Stöhr R,
Hartmann A, Ørntoft T, Dyrskjøt L, Eltze E, Wieland W and Keck B:
MicroRNA profiles of prostate carcinoma detected by multiplatform
microRNA screening. Int J Cancer. 130:611–621. 2012. View Article : Google Scholar
|
|
73
|
Liu B, Li J and Cairns MJ: Identifying
miRNAs, targets and functions. Brief Bioinform. 15:1–19. 2014.
View Article : Google Scholar :
|
|
74
|
Chen CS, Huang CY, Huang SP, Lin VC, Yu
CC, Chang TY and Bao BY: Genetic interaction analysis of TCF7L2 for
biochemical recurrence after radical prostatectomy in localized
prostate cancer. Int J Med Sci. 12:243–247. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Malhotra S, Lapointe J, Salari K, Higgins
JP, Ferrari M, Montgomery K, van de Rijn M, Brooks JD and Pollack
JR: A tri-marker proliferation index predicts biochemical
recurrence after surgery for prostate cancer. PLoS One. 6. pp.
e202932011, View Article : Google Scholar
|
|
76
|
Mo RJ, Han ZD, Liang YK, Ye JH, Wu SL, Lin
SX, Zhang YQ, Song SD, Jiang FN, Zhong WD and Wu CL: Expression of
PD-L1 in tumor-associated nerves correlates with reduced
CD8+ tumor-associated lymphocytes and poor prognosis in
prostate cancer. Int J Cancer. 144:3099–3110. 2019. View Article : Google Scholar
|
|
77
|
Gevensleben H, Dietrich D, Golletz C,
Steiner S, Jung M, Thiesler T, Majores M, Stein J, Uhl B, Müller S,
et al: The immune checkpoint regulator PD-L1 is highly expressed in
aggressive primary prostate cancer. Clin Cancer Res. 22:1969–1977.
2016. View Article : Google Scholar
|
|
78
|
Luo JH, Yu YP, Cieply K, Lin F, Deflavia
P, Dhir R, Finkelstein S, Michalopoulos G and Becich M: Gene
expression analysis of prostate cancers. Mol Carcinog. 33:25–35.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Sandsmark E, Andersen MK, Bofin AM,
Bertilsson H, Drabløs F, Bathen TF, Rye MB and Tessem MB: SFRP4
gene expression is increased in aggressive prostate cancer. Sci
Rep. 7:142762017. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Mortensen MM, Høyer S, Lynnerup AS,
Ørntoft TF, Sørensen KD, Borre M and Dyrskjøt L: Expression
profiling of prostate cancer tissue delineates genes associated
with recurrence after prostatectomy. Sci Rep. 5:160182015.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Mazzoni SM and Fearon ER: AXIN1 and AXIN2
variants in gastrointestinal cancers. Cancer Lett. 355:1–8. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Li J, Hu SB, Wang LY, Zhang X, Zhou X,
Yang B, Li JH, Xiong J, Liu N, Li Y, et al: Autophagy-dependent
generation of Axin2+ cancer stem-like cells promotes
hepatocarcinogenesis in liver cirrhosis. Oncogene. 36:6725–6737.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Martins-Neves SR, Corver WE,
Paiva-Oliveira DI, van den Akker BE, Briaire-de-Bruijn IH, Bovée
JV, Gomes CM and Cleton-Jansen AM: Osteosarcoma stem cells have
active Wnt/β-catenin and overexpress SOX2 and KLF4. J Cell Physiol.
231:876–886. 2016. View Article : Google Scholar
|
|
84
|
Lim X, Tan SH, Yu KL, Lim SB and Nusse R:
Axin2 marks quiescent hair follicle bulge stem cells that are
maintained by autocrine Wnt/β-catenin signaling. Proc Natl Acad Sci
USA. 113:E1498–E1505. 2016. View Article : Google Scholar
|
|
85
|
Ma C, Liu C, Huang P, Kaku H, Chen J, Guo
K, Ueki H, Sakai A, Nasu Y, Kumon H, et al: Significant association
between the Axin2 rs2240308 single nucleotide polymorphism and the
incidence of prostate cancer. Oncol Lett. 8:789–794. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Hu BR, Fairey AS, Madhav A, Yang D, Li M,
Groshen S, Stephens C, Kim PH, Virk N, Wang L, et al: AXIN2
expression predicts prostate cancer recurrence and regulates
invasion and tumor growth. Prostate. 76:597–608. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Nordby Y, Richardsen E, Rakaee M, Ness N,
Donnem T, Patel HR, Busund LT, Bremnes RM and Andersen S: High
expression of PDGFR-β in prostate cancer stroma is independently
associated with clinical and biochemical prostate cancer
recurrence. Sci Rep. 7:433782017. View Article : Google Scholar
|
|
88
|
Paulsson J, Ehnman M and Östman A: PDGF
receptors in tumor biology: Prognostic and predictive potential.
Future Oncol. 10:1695–1708. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Demidenko R, Daniunaite K, Bakavicius A,
Sabaliauskaite R, Skeberdyte A, Petroska D, Laurinavicius A,
Jankevicius F, Lazutka JR and Jarmalaite S: Decreased expression of
MT1E is a potential biomarker of prostate cancer progression.
Oncotarget. 8:61709–61718. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Si M and Lang J: The roles of
metallothioneins in carcinogenesis. J Hematol Oncol. 11:1072018.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Tse KY, Liu VW, Chan DW, Chiu PM, Tam KF,
Chan KK, Liao XY, Cheung AN and Ngan HY: Epigenetic alteration of
the metallothionein 1E gene in human endometrial carcinomas. Tumour
Biol. 30:93–99. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Subrungruanga I, Thawornkunob C,
Chawalitchewinkoon-Petmitrc P, Pairojkul C, Wongkham S and Petmitrb
S: Gene expression profiling of intrahepatic cholangiocarcinoma.
Asian Pac J Cancer Prev. 14:557–563. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Faller WJ, Rafferty M, Hegarty S, Gremel
G, Ryan D, Fraga MF, Esteller M, Dervan PA and Gallagher WM:
Metallothionein 1E is methylated in malignant melanoma and
increases sensitivity to cisplatin-induced apoptosis. Melanoma Res.
20:392–400. 2010.PubMed/NCBI
|
|
94
|
Wer ynska B, Pula B, Muszczynska-Bernhard
B, Gomulkiewicz A, Piotrowska A, Prus R, Podhorska-Okolow M,
Jankowska R and Dziegiel P: Metallothionein 1F and 2A
over-expression predicts poor outcome of non-small cell lung cancer
patients. Exp Mol Pathol. 94:301–308. 2013. View Article : Google Scholar
|
|
95
|
Ferrario C, Lavagni P, Gariboldi M,
Miranda C, Losa M, Cleris L, Formelli F, Pilotti S, Pierotti MA and
Greco A: Metallothionein 1G acts as an oncosupressor in papillary
thyroid carcinoma. Lab Invest. 88:474–481. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Takahashi M, Rhodes DR, Furge KA, Kanayama
H, Kagawa S, Haab BB and Teh BT: Gene expression profiling of clear
cell renal cell carcinoma: Gene identification and prognostic
classification. Proc Natl Acad Sci USA. 98:9754–9759. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Jin R, Bay BH, Chow VT, Tan PH and Lin VC:
Metallothionein 1E mRNA is highly expressed in oestrogen
receptor-negative human invasive ductal breast cancer. Br J Cancer.
83:319–323. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Hur H, Ryu HH, Li CH, Kim IY, Jang WY and
Jung S: Metallothinein 1E enhances glioma invasion through
modulation matrix metalloproteinases-2 and 9 in U87MG mouse brain
tumor model. J Korean Neurosurg Soc. 59:551–558. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Ryu HH, Jung S, Jung TY, Moon KS, Kim IY,
Jeong YI, Jin SG, Pei J, Wen M and Jang WY: Role of metallothionein
1E in the migration and invasion of human glioma cell lines. Int J
Oncol. 41:1305–1313. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Mavridis K, Stravodimos K and Scorilas A:
Quantified KLK15 gene expression levels discriminate prostate
cancer from benign tumors and constitute a novel independent
predictor of disease progression. Prostate. 73:1191–1201. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Obiezu CV and Diamandis EP: Human tissue
kallikrein gene family: Applications in cancer. Cancer Lett.
224:1–22. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Tse BWC, Volpert M, Ratther E, Stylianou
N, Nouri M, McGowan K, Lehman ML, McPherson SJ, Roshan-Moniri M,
Butler MS, et al: Neuropilin-1 is upregulated in the adaptive
response of prostate tumors to androgen-targeted therapies and is
prognostic of metastatic progression and patient mortality.
Oncogene. 36:3417–3427. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Muhl L, Folestad EB, Gladh H, Wang Y,
Moessinger C, Jakobsson L and Eriksson U: Neuropilin 1 binds PDGF-D
and is a co-receptor in PDGF-D-PDGFRβ signaling. J Cell Sci.
130:1365–1378. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Zhang L, Wang H, Li C, Zhao Y, Wu L, Du X
and Han Z: VEGF-A/Neuropilin 1 pathway confers cancer stemness via
activating Wnt/β-catenin axis in breast cancer cells. Cell Physiol
Biochem. 44:1251–1262. 2017. View Article : Google Scholar
|
|
105
|
Latil A, Bièche I, Pesche S, Valéri A,
Fournier G, Cussenot O and Lidereau R: VEGF overexpression in
clinically localized prostate tumors and neuropilin-1
overexpression in metastatic forms. Int J Cancer. 89:167–171. 2000.
View Article : Google Scholar
|
|
106
|
Talagas M, Uguen A, Garlantezec R,
Fournier G, Doucet L, Gobin E, Marcorelles P, Volant A and DE
Braekeleer M: VEGFR1 and NRP1 endothelial expressions predict
distant relapse after radical prostatectomy in clinically localized
prostate cancer. Anticancer Res. 33:2065–2075. 2013.PubMed/NCBI
|
|
107
|
Li F, Xu Y and Liu RL: SAMD5 mRNA was
overexpressed in prostate cancer and can predict biochemical
recurrence after radical prostatectomy. Int Urol Nephrol.
51:443–451. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Matsuo T, Dat le T, Komatsu M, Yoshimaru
T, Daizumoto K, Sone S, Nishioka Y and Katagiri T: Early growth
response 4 is involved in cell proliferation of small cell lung
cancer through transcriptional activation of its downstream genes.
PLoS One. 9:e1136062014. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Yagai T, Matsui S, Harada K, Inagaki FF,
Saijou E, Miura Y, Nakanuma Y, Miyajima A and Tanaka M: Expression
and localization of sterile alpha motif domain containing 5 is
associated with cell type and malignancy of biliary tree. PLoS One.
12:e01753552017. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Watanabe T, Kobunai T, Akiyoshi T, Matsuda
K, Ishihara S and Nozawa K: Prediction of response to preoperative
chemo-radiotherapy in rectal cancer by using reverse transcriptase
polymerase chain reaction analysis of four genes. Dis Colon Rectum.
57:23–31. 2014. View Article : Google Scholar
|
|
111
|
Wang Y, Shang Y, Li J, Chen W, Li G, Wan
J, Liu W and Zhang M: Specific Eph receptor-cytoplasmic effector
signaling mediated by SAM-SAM domain interactions. Elife. 7:pii:
e35677. 2018.
|
|
112
|
Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang
J, Perry SR, Labrot ES, Wu X, Lis R, et al: SMAD4-dependent barrier
constrains prostate cancer growth and metastatic progression.
Nature. 470:269–273. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Zhang DT, Shi JG, Liu Y and Jiang HM: The
prognostic value of Smad4 mRNA in patients with prostate cancer.
Tumour Biol. 35:3333–3337. 2014. View Article : Google Scholar
|
|
114
|
Guo J, Wang M, Wang Z and Liu X:
Overexpression of pleomor-phic adenoma gene-like 2 is a novel poor
prognostic marker of prostate cancer. PLoS One. 11:e01586672016.
View Article : Google Scholar
|
|
115
|
Li N, Li D, Du Y, Su C, Yang C, Lin C, Li
X and Hu G: Overexpressed PLAGL2 transcriptionally activates Wnt6
and promotes cancer development in colorectal cancer. Oncol Rep.
41:875–884. 2019.
|
|
116
|
Zheng H, Ying H, Wiedemeyer R, Yan H,
Quayle SN, Ivanova EV, Paik JH, Zhang H, Xiao Y, Perry SR, et al:
PLAGL2 regulates Wnt signaling to impede differentiation in neural
stem cells and gliomas. Cancer Cell. 17:497–509. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Landrette SF, Kuo YH, Hensen K, Barjesteh
van Waalwijk van Doorn-Khosrovani S, Perrat PN, Van de Ven WJ,
Delwel R and Castilla LH: Plag1 and Plagl2 are oncogenes that
induce acute myeloid leukemia in cooperation with Cbfb-MYH11.
Blood. 105:2900–2907. 2005. View Article : Google Scholar
|
|
118
|
Landrette SF, Madera D, He F and Castilla
LH: The transcription factor PlagL2 activates Mpl transcription and
signaling in hematopoietic progenitor and leukemia cells. Leukemia.
25:655–662. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Zhao SG, Lehrer J, Chang SL, Das R, Erho
N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, et al: The
immune landscape of prostate cancer and nomination of PD-L2 as a
potential therapeutic target. J Natl Cancer Inst. 111:301–310.
2019. View Article : Google Scholar
|
|
120
|
Kladi-Skandali A, Mavridis K, Scorilas A
and Sideris DC: Expressional profiling and clinical relevance of
RNase kappa in prostate cancer: A novel indicator of favorable
progression-free survival. J Cancer Res Clin Oncol. 144:2049–2057.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Gkratsou AS, Fragoulis EG and Sideris DC:
Effect of cytostatic drugs on the mRNA expression levels of
ribonuclease κ in breast and ovarian cancer cells. Anticancer
Agents Med Chem. 14:400–408. 2014. View Article : Google Scholar
|
|
122
|
Ma X, Du T, Zhu D, Chen X, Lai Y, Wu W,
Wang Q, Lin C, Li Z, Liu L and Huang H: High levels of glioma tumor
suppressor candidate region gene 1 predicts a poor prognosis for
prostate cancer. Oncol Lett. 16:6749–6755. 2018.PubMed/NCBI
|
|
123
|
Yang P, Kollmeyer TM, Buckner K, Bamlet W,
Ballman KV and Jenkins RB: Polymorphisms in GLTSCR1 and ERCC2 are
associated with the development of oligodendrogliomas. Cancer.
103:2363–2372. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Alpsoy A and Dykhuizen EC: Glioma tumor
suppressor candidate region gene 1 (GLTSCR1) and its paralog
GLTSCR1-like form SWI/SNF chromatin remodeling subcomplexes. J Biol
Chem. 293:3892–3903. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Gu Y, Chow MJ, Kapoor A, Mei W, Jiang Y,
Yan J, De Melo J, Seliman M, Yang H, Cutz JC, et al: Biphasic
alteration of butyrylcholinesterase (BChE) during prostate cancer
development. Transl Oncol. 11:1012–1022. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Chatonnet A and Lockridge O: Comparison of
butyrylcholines-terase and acetylcholinesterase. Biochem J.
260:625–634. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Evans FT, Gray PW, Lehmann H and Silk E:
Sensitivity to succinylcholine in relation to serum-cholinesterase.
Lancet. 1:1229–1230. 1952. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
De Vriese C, Gregoire F, Lema-Kisoka R,
Waelbroeck M, Robberecht P and Delporte C: Ghrelin degradation by
serum and tissue homogenates: Identification of the cleavage sites.
Endocrinology. 145:4997–5005. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Brimijoin S, Gao Y, Geng L and Chen VP:
Treating cocaine addiction, obesity, and emotional disorders by
viral gene transfer of butyrylcholinesterase. Front Pharmacol.
9:1122018. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Schopfer LM, Lockridge O and Brimijoin S:
Pure human butyrylcholinesterase hydrolyzes octanoyl ghrelin to
desacyl ghrelin. Gen Comp Endocrinol. 224:61–68. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Brimijoin S, Chen VP, Pang YP, Geng L and
Gao Y: Physiological roles for butyrylcholinesterase: A
BChE-ghrelin axis. Chem Biol Interact. 259:271–275. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Erho N, Crisan A, Vergara IA, Mitra AP,
Ghadessi M, Buerki C, Bergstralh EJ, Kollmeyer T, Fink S, Haddad Z,
et al: Discovery and validation of a prostate cancer genomic
classifier that predicts early metastasis following radical
prostatectomy. PLoS One. 8:e668552013. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Karnes RJ, Bergstralh EJ, Davicioni E,
Ghadessi M, Buerki C, Mitra AP, Crisan A, Erho N, Vergara IA, Lam
LL, et al: Validation of a genomic classifier that predicts
metastasis following radical prostatectomy in an at risk patient
population. J Urol. 190:2047–2053. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Klein EA, Haddad Z, Yousefi K, Lam LL,
Wang Q, Choeurng V, Palmer-Aronsten B, Buerki C, Davicioni E, Li J,
et al: Decipher genomic classifier measured on prostate biopsy
predicts metastasis risk. Urology. 90:148–152. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Knezevic D, Goddard AD, Natraj N,
Cherbavaz DB, Clark-Langone KM, Snable J, Watson D, Falzarano SM,
Magi-Galluzzi C, Klein EA and Quale C: Analytical validation of the
Oncotype DX prostate cancer assay-a clinical RT-PCR assay optimized
for prostate needle biopsies. BMC Genomics. 14:6902013. View Article : Google Scholar
|
|
136
|
Klein EA, Cooperberg MR, Magi-Galluzzi C,
Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis
AC, et al: A 17-gene assay to predict prostate cancer
aggressiveness in the context of Gleason grade heterogeneity, tumor
multifocality, and biopsy undersampling. Eur Urol. 66:550–560.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Cuzick J, Swanson GP, Fisher G, Brothman
AR, Berney DM, Reid JE, Mesher D, Speights VO, Stankiewicz E,
Foster CS, et al: Prognostic value of an RNA expression signature
derived from cell cycle proliferation genes in patients with
prostate cancer: A retrospective study. Lancet Oncol. 12:245–255.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Oderda M, Cozzi G, Daniele L, Sapino A,
Munegato S, Renne G, De Cobelli O and Gontero P: Cell-cycle
Progression-score might improve the current risk assessment in
newly diagnosed prostate cancer patients. Urology. 102:73–78. 2017.
View Article : Google Scholar
|
|
139
|
Albala D, Kemeter MJ, Febbo PG, Lu R, John
V, Stoy D, Denes B, McCall M, Shindel AW and Dubeck F: Health
economic impact and prospective clinical utility of oncotype DX®
genomic prostate score. Rev Urol. 18:123–132. 2016.
|
|
140
|
Cullen J, Rosner IL, Brand TC, Zhang N,
Tsiatis AC, Moncur J, Ali A, Chen Y, Knezevic D, Maddala T, et al:
A Biopsy-based 17-gene genomic prostate score predicts recurrence
after radical prostatectomy and adverse surgical pathology in a
racially diverse population of men with clinically low- and
intermediate-risk prostate cancer. Eur Urol. 68:123–131. 2015.
View Article : Google Scholar
|
|
141
|
Cooperberg MR, Simko JP, Cowan JE, Reid
JE, Djalilvand A, Bhatnagar S, Gutin A, Lanchbury JS, Swanson GP,
Stone S and Carroll PR: Validation of a cell-cycle progression gene
panel to improve risk stratification in a contemporary
prostatectomy cohort. J Clin Oncol. 31:1428–1434. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Van Den Eeden SK, Lu R, Zhang N,
Quesenberry CP Jr, Shan J, Han JS, Tsiatis AC, Leimpeter AD,
Lawrence HJ, Febbo PG and Presti JC: A Biopsy-based 17-gene genomic
prostate score as a predictor of metastases and prostate cancer
death in surgically treated men with clinically localized disease.
Eur Urol. 73:129–138. 2018. View Article : Google Scholar
|
|
143
|
Eggener S, Karsh LI, Richardson T, Shindel
AW, Lu R, Rosenberg S, Goldfischer E, Korman H, Bennett J, Newmark
J and Denes BS: A 17-gene panel for prediction of adverse prostate
cancer pathologic features: Prospective clinical validation and
utility. Urology. 126:76–82. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Mosley JD and Keri RA: Cell cycle
correlated genes dictate the prognostic power of breast cancer gene
lists. BMC Med Genomics. 1:112008. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Freedland SJ, Gerber L, Reid J, Welbourn
W, Tikishvili E, Park J, Younus A, Gutin A, Sangale Z, Lanchbury
JS, et al: Prognostic utility of cell cycle progression score in
men with prostate cancer after primary external beam radiation
therapy. Int J Radiat Oncol Biol Phys. 86:848–853. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Bishoff JT, Freedland SJ, Gerber L,
Tennstedt P, Reid J, Welbourn W, Graefen M, Sangale Z, Tikishvili
E, Park J, et al: Prognostic utility of the cell cycle progression
score generated from biopsy in men treated with prostatectomy. J
Urol. 192:409–414. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Tosoian JJ, Chappidi MR, Bishoff JT,
Freedland SJ, Reid J, Brawer M, Stone S, Schlomm T and Ross AE:
Prognostic utility of biopsy-derived cell cycle progression score
in patients with National Comprehensive Cancer Network low-risk
prostate cancer undergoing radical prostatectomy: Implications for
treatment guidance. BJU Int. 120:808–814. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Cuzick J, Berney DM, Fisher G, Mesher D,
Møller H, Reid JE, Perry M, Park J, Younus A, Gutin A, et al:
Prognostic value of a cell cycle progression signature for prostate
cancer death in a conservatively managed needle biopsy cohort. Br J
Cancer. 106:1095–1099. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Health Quality Ontario: Prolaris cell
cycle progression test for localized prostate cancer: A health
technology assessment. Ont Health Technol Assess Ser. 17:1–75.
2017.
|
|
150
|
Li F, Ji JP, Xu Y and Liu RL:
Identification a novel set of 6 differential expressed genes in
prostate cancer that can potentially predict biochemical recurrence
after curative surgery. Clin Transl Oncol. 21:1067–1075. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Chu J, Li N and Gai W: Identification of
genes that predict the biochemical recurrence of prostate cancer.
Oncol Lett. 16:3447–3452. 2018.PubMed/NCBI
|
|
152
|
Abou-Ouf H, Alshalalfa M, Takhar M, Erho
N, Donnelly B, Davicioni E, Karnes RJ and Bismar TA: Validation of
a 10-gene molecular signature for predicting biochemical recurrence
and clinical metastasis in localized prostate cancer. J Cancer Res
Clin Oncol. 144:883–891. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Russo MA, Ravenna L, Pellegrini L,
Petrangeli E, Salvatori L, Magrone T, Fini M and Tafani M: Hypoxia
and inflammation in prostate cancer progression. Cross-talk with
androgen and estrogen receptors and cancer stem cells. Endocr Metab
Immune Disord Drug Targets. 16:235–248. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Marignol L, Rivera-Figueroa K, Lynch T and
Hollywood D: Hypoxia, notch signalling, and prostate cancer. Nat
Rev Urol. 10:405–413. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Yang L, Roberts D, Takhar M, Erho N, Bibby
BAS, Thiruthaneeswaran N, Bhandari V, Cheng WC, Haider S, McCorry
AMB, et al: Development and validation of a 28-gene Hypoxia-related
prognostic signature for localized prostate cancer. EBioMedicine.
31:182–189. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Jiang Y, Mei W, Gu Y, Lin X, He L, Zeng H,
Wei F, Wan X, Yang H, Major P and Tang D: Construction of a set of
novel and robust gene expression signatures predicting prostate
cancer recurrence. Mol Oncol. 12:1559–1578. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Apostolopoulos V, Stojanovska L and
Gargosky SE: MUC1 (CD227): A multi-tasked molecule. Cell Mol Life
Sci. 72:4475–4500. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Kufe DW: Mucins in cancer: Function,
prognosis and therapy. Nat Rev Cancer. 9:874–885. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Nath S and Mukherjee P: MUC1: A
multifaceted oncoprotein with a key role in cancer progression.
Trends Mol Med. 20:332–342. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Wurz GT, Kao CJ, Wolf M and DeGregorio MW:
Tecemotide: An antigen-specific cancer immunotherapy. Hum Vaccin
Immunother. 10:3383–3393. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Eminaga O, Wei W, Hawley SJ, Auman H,
Newcomb LF, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Carroll
PR, et al: MUC1 expression by immunohistochemistry is associated
with adverse pathologic features in prostate cancer: A
Multi-institutional Study. PLoS One. 11:e01652362016. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Wong N, Major P, Kapoor A, Wei F, Yan J,
Aziz T, Zheng M, Jayasekera D, Cutz JC, Chow MJ and Tang D:
Amplification of MUC1 in prostate cancer metastasis and CRPC
development. Oncotarget. 7:83115–83133. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Lin X, Gu Y, Kapoor A, Wei F, Aziz T, Ojo
D, Jiang Y, Bonert M, Shayegan B, Yang H, et al: Overexpression of
MUC1 and genomic alterations in its network associate with prostate
cancer progression. Neoplasia. 19:857–867. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Tarnowski M, Czerewaty M, Deskur A,
Safranow K, Marlicz W, Urasińska E, Ratajczak MZ and Starzyńska T:
Expression of cancer testis antigens in colorectal cancer: New
prognostic and therapeutic implications. Dis Markers.
2016:19875052016. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Stellfox ME, Nardi IK, Knippler CM and
Foltz DR: Differential binding partners of the Mis18a/β YIPPEE
domains regulate Mis18 complex recruitment to centromeres. Cell
Rep. 15:2127–2135. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Nardi IK, Zasadzińska E, Stellfox ME,
Knippler CM and Foltz DR: Licensing of centromeric chromatin
assembly through the Mis18a-Mis18β heterotetramer. Mol Cell.
61:774–787. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Wang D, Chen Z, Lin F, Wang Z, Gao Q, Xie
H, Xiao H, Zhou Y, Zhang F, Ma Y, et al: OIP 5 promotes growth,
metastasis and chemoresistance to cisplatin in bladder cancer
cells. J Cancer. 9:4684–4695. 2018. View Article : Google Scholar :
|
|
168
|
He J, Zhao Y, Zhao E, Wang X, Dong Z, Chen
Y, Yang L and Cui H: Cancer-testis specific gene OIP5: A downstream
gene of E2F1 that promotes tumorigenesis and metastasis in
glioblastoma by stabilizing E2F1 signaling. Neuro Oncol.
20:1173–1184. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Gong M, Xu Y, Dong W, Guo G, Ni W, Wang Y,
Wang Y and An R: Expression of Opa interacting protein 5 (OIP5) is
associated with tumor stage and prognosis of clear cell renal cell
carcinoma. Acta Histochem. 115:810–815. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Chun HK, Chung KS, Kim HC, Kang JE, Kang
MA, Kim JT, Choi EH, Jung KE, Kim MH, Song EY, et al: OIP5 is a
highly expressed potential therapeutic target for colorectal and
gastric cancers. BMB Rep. 43:349–354. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Mobasheri MB, Shirkoohi R and Modarressi
MH: Cancer/Testis OIP5 and TAF7L Genes are Up-regulated in breast
cancer. Asian Pac J Cancer Prev. 16:4623–4628. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
López-Urrutia E, Bustamante Montes LP,
Ladrón de Guevara Cervantes D, Pèrez-Plasencia C and Campos-Parra
AD: Crosstalk between long Non-coding RNAs, Micro-RNAs and mRNAs:
Deciphering molecular mechanisms of master regulators in cancer.
Front Oncol. 9:6692019. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Salmena L, Poliseno L, Tay Y, Kats L and
Pandolfi PP: A ceRNA hypothesis: The Rosetta stone of a hidden RNA
language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Ramnarine VR, Kobelev M, Gibb EA, Nouri M,
Lin D, Wang Y, Buttyan R, Davicioni E, Zoubeidi A and Collins CC:
The evolution of long noncoding RNA acceptance in prostate cancer
initiation and progression, and its clinical utility in disease
management. Eur Urol. Aug 22–2019.Epub ahead of print. View Article : Google Scholar
|
|
175
|
Bussemakers MJ, van Bokhoven A, Verhaegh
GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N and Isaacs
WB: DD3: A new prostate-specific gene, highly overexpressed in
prostate cancer. Cancer Res. 59:5975–5979. 1999.PubMed/NCBI
|
|
176
|
Crawford ED, Rove KO, Trabulsi EJ, Qian J,
Drewnowska KP, Kaminetsky JC, Huisman TK, Bilowus ML, Freedman SJ,
Glover WL Jr and Bostwick DG: Diagnostic performance of PCA3 to
detect prostate cancer in men with increased prostate specific
antigen: A prospective study of 1,962 cases. J Urol. 188:1726–1731.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Deras IL, Aubin SM, Blase A, Day JR, Koo
S, Partin AW, Ellis WJ, Marks LS, Fradet Y, Rittenhouse H and
Groskopf J: PCA3: A molecular urine assay for predicting prostate
biopsy outcome. J Urol. 179:1587–1592. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Gittelman MC, Hertzman B, Bailen J,
Williams T, Koziol I, Henderson RJ, Efros M, Bidair M and Ward JF:
PCA3 molecular urine test as a predictor of repeat prostate biopsy
outcome in men with previous negative biopsies: A prospecAive
multicenter clinical study. J Urol. 190:64–69. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Ma W, Chen X, Ding L, Ma J, Jing W, Lan T,
Sattar H, Wei Y, Zhou F and Yuan Y: The prognostic value of long
noncoding RNAs in prostate cancer: A systematic review and
meta-analysis. Oncotarget. 8:57755–57765. 2017.PubMed/NCBI
|
|
180
|
Wu XL, Zhang JW, Li BS, Peng SS and Yuan
YQ: The prognostic value of abnormally expressed lncRNAs in
prostatic carcinoma: A systematic review and meta-analysis.
Medicine (Baltimore). 96:e92792017. View Article : Google Scholar
|
|
181
|
Wang J, Cheng G, Li X, Pan Y, Qin C, Yang
H, Hua L and Wang Z: Overexpression of long non-coding RNA
LOC400891 promotes tumor progression and poor prognosis in prostate
cancer. Tumour Biol. 37:9603–9613. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Xu S, Yi XM, Tang CP, Ge JP, Zhang ZY and
Zhou WQ: Long non-coding RNA ATB promotes growth and
epithelial-mesen-chymal transition and predicts poor prognosis in
human prostate carcinoma. Oncol Rep. 36:10–22. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ,
Tao QF, Liu F, Pan W, Wang TT, Zhou CC, et al: A long noncoding RNA
activated by TGF-β promotes the invasion-metastasis cascade in
hepatocel-lular carcinoma. Cancer Cell. 25:666–681. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Xiao H, Zhang F, Zou Y, Li J, Liu Y and
Huang W: The function and mechanism of long Non-coding RNA-ATB in
cancers. Front Physiol. 9:3212018. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Wu J, Cheng G, Zhang C, Zheng Y, Xu H,
Yang H and Hua L: Long noncoding RNA LINC01296 is associated with
poor prognosis in prostate cancer and promotes cancer-cell
proliferation and metastasis. Onco Targets Ther. 10:1843–1852.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Qiu JJ and Yan JB: Long non-coding RNA
LINC01296 is a potential prognostic biomarker in patients with
colorectal cancer. Tumour Biol. 36:7175–7183. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Seitz AK, Christensen LL, Christensen E,
Faarkrog K, Ostenfeld MS, Hedegaard J, Nordentoft I, Nielsen MM,
Palmfeldt J, Thomson M, et al: Profiling of long non-coding RNAs
identifies LINC00958 and LINC01296 as candidate oncogenes in
bladder cancer. Sci Rep. 7:3952017. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Wang K, Zhang M, Wang C and Ning X: Long
Noncoding RNA LINC01296 Harbors miR-21a to regulate colon carcinoma
proliferation and invasion. Oncol Res. 27:541–549. 2019. View Article : Google Scholar
|
|
189
|
Qin QH, Yin ZQ, Li Y, Wang BG and Zhang
MF: Long inter-genic noncoding RNA 01296 aggravates gastric cancer
cells progress through miR-122/MMP-9. Biomed Pharmacother.
97:450–457. 2018. View Article : Google Scholar
|
|
190
|
Zhang D, Li H, Xie J, Jiang D, Cao L, Yang
X, Xue P and Jiang X: Long noncoding RNA LINC01296 promotes tumor
growth and progression by sponging miR-5095 in human
cholangiocarcinoma. Int J Oncol. 52:1777–1786. 2018.PubMed/NCBI
|
|
191
|
Jiang M, Xiao Y, Liu D, Luo N, Gao Q and
Guan Y: Overexpression of long noncoding RNA LINC01296 indicates an
unfavorable prognosis and promotes tumorigenesis in breast cancer.
Gene. 675:217–224. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Hu X, Duan L, Liu H and Zhang L: Long
noncoding RNA LINC01296 induces non-small cell lung cancer growth
and progression through sponging miR-5095. Am J Transl Res.
11:895–903. 2019.PubMed/NCBI
|
|
193
|
Feng W, Zhai C, Shi W, Zhang Q, Yan X,
Wang J, Wang Q and Li M: Clinicopathological and prognostic value
of LINC01296 in cancers: A meta-analysis. Artif Cells Nanomed
Biotechnol. 47:3315–3321. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Wan Y, Li M and Huang P: LINC01296
promotes proliferation, migration, and invasion of HCC cells by
targeting miR-122-5P and modulating EMT activity. Onco Targets
Ther. 12:2193–2203. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Prensner JR, Iyer MK, Sahu A, Asangani IA,
Cao Q, Patel L, Vergara IA, Davicioni E, Erho N, Ghadessi M, et al:
The long noncoding RNA SChLAP1 promotes aggressive prostate cancer
and antagonizes the SWI/SNF complex. Nat Genet. 45:1392–1398. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Mehra R, Udager AM, Ahearn TU, Cao X, Feng
FY, Loda M, Petimar JS, Kantoff P, Mucci LA and Chinnaiyan AM:
Overexpression of the long Non-coding RNA SChLAP1 independently
predicts lethal prostate cancer. Eur Urol. 70:549–552. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Prensner JR, Zhao S, Erho N, Schipper M,
Iyer MK, Dhanasekaran SM, Magi-Galluzzi C, Mehra R, Sahu A,
Siddiqui J, et al: RNA biomarkers associated with metastatic
progression in prostate cancer: A multi-institutional
high-throughput analysis of SChLAP1. Lancet Oncol. 15:1469–1480.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Mehra R, Shi Y, Udager AM, Prensner JR,
Sahu A, Iyer MK, Siddiqui J, Cao X, Wei J, Jiang H, et al: A novel
RNA in situ hybridization assay for the long noncoding RNA SChLAP1
predicts poor clinical outcome after radical prostatectomy in
clinically localized prostate cancer. Neoplasia. 16:1121–1127.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Raab JR, Smith KN, Spear CC, Manner CJ,
Calabrese JM and Magnuson T: SWI/SNF remains localized to chromatin
in the presence of SCHLAP1. Nat Genet. 51:26–29. 2019. View Article : Google Scholar :
|
|
200
|
Fotouhi Ghiam A, Taeb S, Huang X, Huang V,
Ray J, Scarcello S, Hoey C, Jahangiri S, Fokas E, Loblaw A, et al:
Long non-coding RNA urothelial carcinoma associated 1 (UCA1)
mediates radiation response in prostate cancer. Oncotarget.
8:4668–4689. 2017.
|
|
201
|
Na XY, Liu ZY, Ren PP, Yu R and Shang XS:
Long non-coding RNA UCA1 contributes to the progression of prostate
cancer and regulates proliferation through KLF4-KRT6/13 signaling
pathway. Int J Clin Exp Med. 8:12609–12616. 2015.PubMed/NCBI
|
|
202
|
Wang F, Zhou J, Xie X, Hu J, Chen L, Hu Q,
Guo H and Yu C: Involvement of SRPK1 in cisplatin resistance
related to long non-coding RNA UCA1 in human ovarian cancer cells.
Neoplasma. 62:432–438. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Zheng Q, Wu F, Dai WY, Zheng DC, Zheng C,
Ye H, Zhou B, Chen JJ and Chen P: Aberrant expression of UCA1 in
gastric cancer and its clinical significance. Clin Transl Oncol.
17:640–646. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Tian Y, Zhang X, Hao Y, Fang Z and He Y:
Potential roles of abnormally expressed long noncoding RNA UCA1 and
Malat-1 in metastasis of melanoma. Melanoma Res. 24:335–341. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Chen P, Wan D, Zheng D, Zheng Q, Wu F and
Zhi Q: Long non-coding RNA UCA1 promotes the tumorigenesis in
pancreatic cancer. Biomed Pharmacother. 83:1220–1226. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Zhao W, Sun C and Cui Z: A long noncoding
RNA UCA1 promotes proliferation and predicts poor prognosis in
glioma. Clin Transl Oncol. 19:735–741. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Xuan W, Yu H, Zhang X and Song D:
Crosstalk between the lncRNA UCA1 and microRNAs in cancer. FEBS
Lett. 593:1901–1914. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Zhang S, Dong X, Ji T, Chen G and Shan L:
Long non-coding RNA UCA1 promotes cell progression by acting as a
competing endogenous RNA of ATF2 in prostate cancer. Am J Transl
Res. 9:366–375. 2017.PubMed/NCBI
|
|
209
|
He C, Lu X, Yang F, Qin L, Guo Z, Sun Y
and Wu J: LncRNA UCA1 acts as a sponge of miR-204 to up-regulate
CXCR4 expression and promote prostate cancer progression. Biosci
Rep. 39:pii: BSR20181465. 2019. View Article : Google Scholar
|
|
210
|
Shukla S, Zhang X, Niknafs YS, Xiao L,
Mehra R, Cieślik M, Ross A, Schaeffer E, Malik B, Guo S, et al:
Identification and validation of PCAT14 as prognostic biomarker in
prostate cancer. Neoplasia. 18:489–499. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
White NM, Zhao SG, Zhang J, Rozycki EB,
Dang HX, McFadden SD, Eteleeb AM, Alshalalfa M, Vergara IA, Erho N,
et al: Multi-institutional analysis shows that low PCAT-14
expression associates with poor outcomes in prostate cancer. Eur
Urol. 71:257–266. 2017. View Article : Google Scholar
|
|
212
|
Wang Y, Hu Y, Wu G, Yang Y, Tang Y, Zhang
W, Wang K, Liu Y, Wang X and Li T: Long noncoding RNA PCAT-14
induces proliferation and invasion by hepatocellular carcinoma
cells by inducing methylation of miR-372. Oncotarget.
8:34429–34441. 2017.PubMed/NCBI
|
|
213
|
Huang TB, Dong CP, Zhou GC, Lu SM, Luan Y,
Gu X, Liu L and Ding XF: A potential panel of four-long noncoding
RNA signature in prostate cancer predicts biochemical
recurrence-free survival and disease-free survival. Int Urol
Nephrol. 49:825–835. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Shao N, Tang H, Qu Y, Wan F and Ye D:
Development and validation of lncRNAs-based nomogram for prediction
of biochemical recurrence in prostate cancer by bioinformatics
analysis. J Cancer. 10:2927–2934. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
215
|
Shao N, Zhu Y, Wan FN and Ye DW:
Identification of seven long noncoding RNAs signature for
prediction of biochemical recurrence in prostate cancer. Asian J
Androl. Mar 5–2019.Epub ahead of print. PubMed/NCBI
|
|
216
|
Xu J, Lan Y, Yu F, Zhu S, Ran J, Zhu J,
Zhang H, Li L, Cheng S, Xiao Y and Li X: Transcriptome analysis
reveals a long non-coding RNA signature to improve biochemical
recurrence prediction in prostate cancer. Oncotarget.
9:24936–24949. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Diao P, Song Y, Ge H, Wu Y, Li J, Zhang W,
Wang Y and Cheng J: Identification of 4-lncRNA prognostic signature
in head and neck squamous cell carcinoma. J Cell Biochem.
120:10010–10020. 2019. View Article : Google Scholar
|
|
218
|
Zhang J, Yin M, Peng G and Zhao Y: CRNDE:
An important oncogenic long non-coding RNA in human cancers. Cell
Prolif. 51:e124402018. View Article : Google Scholar : PubMed/NCBI
|
|
219
|
Li J, Zhang Z, Xiong L, Guo C, Jiang T,
Zeng L, Li G and Wang J: SNHG1 lncRNA negatively regulates
miR-199a-3p to enhance CDK7 expression and promote cell
proliferation in prostate cancer. Biochem Biophys Res Commun.
487:146–152. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
220
|
Thin KZ, Tu JC and Raveendran S: Long
non-coding SNHG1 in cancer. Clin Chim Acta. 494:38–47. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
221
|
Sun M, Geng D, Li S, Chen Z and Zhao W:
LncRNA PART1 modulates toll-like receptor pathways to influence
cell proliferation and apoptosis in prostate cancer cells. Biol
Chem. 399:387–395. 2018. View Article : Google Scholar
|
|
222
|
Zhu D, Yu Y, Wang W, Wu K, Liu D, Yang Y,
Zhang C, Qi Y and Zhao S: Long noncoding RNA PART1 promotes
progression of non-small cell lung cancer cells via JAK-STAT
signaling pathway. Cancer Med. Aug 22–2019.Epub ahead of print.
View Article : Google Scholar
|
|
223
|
Hu X, Feng H, Huang H, Gu W, Fang Q, Xie
Y, Qin C and Hu X: Downregulated long noncoding RNA PART1 inhibits
proliferation and promotes apoptosis in bladder cancer. Technol
Cancer Res Treat. 18:15330338198466382019. View Article : Google Scholar : PubMed/NCBI
|
|
224
|
Zhihua Z, Weiwei W, Lihua N, Jianying Z
and Jiang G: p53-induced long non-coding RNA PGM5-AS1 inhibits the
progression of esophageal squamous cell carcinoma through
regulating miR-466/PTEN axis. IUBMB Life. 71:1492–1502. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
225
|
Liu Q, Wu Y, Xiao J and Zou J: Long
Non-coding RNA prostate cancer-associated Transcript 7 (PCAT7)
induces poor prognosis and promotes tumorigenesis by inhibiting
mir-134-5p in Non-small-cell lung (NSCLC). Med Sci Monit.
23:6089–6098. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
226
|
Yuan Q, Chu H, Ge Y, Ma G, Du M, Wang M,
Zhang Z and Zhang W: LncRNA PCAT1 and its genetic variant rs1902432
are associated with prostate cancer risk. J Cancer. 9:1414–1420.
2018. View Article : Google Scholar :
|
|
227
|
Shang Z, Yu J, Sun L, Tian J, Zhu S, Zhang
B, Dong Q, Jiang N, Flores-Morales A, Chang C and Niu Y: LncRNA
PCAT1 activates AKT and NF-kappaB signaling in castration-resistant
prostate cancer by regulating the PHLPP/FKBP51/IKKa complex.
Nucleic Acids Res. 47:4211–4225. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
228
|
Han Y, Rand KA, Hazelett DJ, Ingles SA,
Kittles RA, Strom SS, Rybicki BA, Nemesure B, Isaacs WB, Stanford
JL, et al: Prostate cancer susceptibility in men of african
ancestry at 8q24. J Natl Cancer Inst. 108:2016. View Article : Google Scholar
|
|
229
|
Huang L, Wang Y, Chen J, Wang Y, Zhao Y,
Wang Y, Ma Y, Chen X, Liu W, Li Z, et al: Long noncoding RNA PCAT1,
a novel serum-based biomarker, enhances cell growth by sponging
miR-326 in oesophageal squamous cell carcinoma. Cell Death Dis.
10:5132019. View Article : Google Scholar : PubMed/NCBI
|
|
230
|
Yang ML, Huang Z, Wu LN, Wu R, Ding HX and
Wang BG: lncRNA-PCAT1 rs2632159 polymorphism could be a biomarker
for colorectal cancer susceptibility. Biosci Rep. 39:pii:
BSR20190708. 2019. View Article : Google Scholar
|
|
231
|
Zhao X, Fan Y, Lu C, Li H, Zhou N, Sun G
and Fan H: PCAT1 is a poor prognostic factor in endometrial
carcinoma and associated with cancer cell proliferation, migration
and invasion. Bosn J Basic Med Sci. 19:274–281. 2019.PubMed/NCBI
|
|
232
|
Bartolomei MS, Zemel S and Tilghman SM:
Parental imprinting of the mouse H19 gene. Nature. 351:153–155.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
233
|
Brockdorff N, Ashworth A, Kay GF, McCabe
VM, Norris DP, Cooper PJ, Swift S and Rastan S: The product of the
mouse Xist gene is a 15 kb inactive X-specific transcript
containing no conserved ORF and located in the nucleus. Cell.
71:515–526. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
234
|
Ward JF and Moul JW: Biochemical
recurrence after definitive prostate cancer therapy. Part I:
Defining and localizing biochemical recurrence of prostate cancer.
Curr Opin Urol. 15:181–186. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
235
|
Ward JF and Moul JW: Biochemical
recurrence after definitive prostate cancer therapy. Part II:
Treatment strategies for biochemical recurrence of prostate cancer.
Curr Opin Urol. 15:187–195. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
236
|
McCormick BZ, Mahmoud AM, Williams SB and
Davis JW: Biochemical recurrence after radical prostatectomy:
Current status of its use as a treatment endpoint and early
management strategies. Indian J Urol. 35:6–17. 2019.PubMed/NCBI
|
|
237
|
Spratt DE, McHugh DJ, Morris MJ and
Morgans AK: Management of biochemically recurrent prostate cancer:
Ensuring the right treatment of the right patient at the right
time. Am Soc Clin Oncol Educ Book. 38:355–362. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
238
|
Gillessen S, Attard G, Beer TM, Beltran H,
Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, et
al: Management of patients with advanced prostate cancer: The
report of the advanced prostate cancer consensus conference APCCC
2017. Eur Urol. 73:178–211. 2018. View Article : Google Scholar
|
|
239
|
Rahbar K, Afshar-Oromieh A, Jadvar H and
Ahmadzadehfar H: PSMA theranostics: Current status and future
directions. Mol Imaging. 17:15360121187760682018. View Article : Google Scholar : PubMed/NCBI
|
|
240
|
Wester HJ and Schottelius M: PSMA-Targeted
radiopharmaceu-ticals for imaging and therapy. Semin Nucl Med.
49:302–312. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
241
|
O'Keefe DS, Bacich DJ, Huang SS and Heston
WDW: A perspective on the evolving story of PSMA biology,
PSMA-based imaging, and endoradiotherapeutic strategies. J Nucl
Med. 59:1007–1013. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
242
|
Israeli RS, Powell CT, Corr JG, Fair WR
and Heston WD: Expression of the prostate-specific membrane
antigen. Cancer Res. 54:1807–1811. 1994.PubMed/NCBI
|
|
243
|
Sweat SD, Pacelli A, Murphy GP and
Bostwick DG: Prostate-specific membrane antigen expression is
greatest in prostate adenocarcinoma and lymph node metastases.
Urology. 52:637–640. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
244
|
Wright GL Jr, Grob BM, Haley C, Grossman
K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF and
Moriarty R: Upregulation of prostate-specific membrane antigen
after androgen-deprivation therapy. Urology. 48:326–334. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
245
|
Marchal C, Redondo M, Padilla M, Caballero
J, Rodrigo I, García J, Quian J and Boswick DG: Expression of
prostate specific membrane antigen (PSMA) in prostatic
adenocarcinoma and prostatic intraepithelial neoplasia. Histol
Histopathol. 19:715–718. 2004.PubMed/NCBI
|
|
246
|
Sheikhbahaei S, Werner RA, Solnes LB,
Pienta KJ, Pomper MG, Gorin MA and Rowe SP: Prostate-specific
membrane antigen (PSMA)-targeted PET imaging of prostate cancer: An
update on important pitfalls. Semin Nucl Med. 49:255–270. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
247
|
Bouchelouche K and Sathekge MM: Letter
from the editors. Semin Nucl Med. 49:245–246. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
248
|
Fendler WP, Calais J, Eiber M, Flavell RR,
Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, et
al: Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent
prostate cancer: A prospective Single-Arm clinical trial. JAMA
Oncol. 5:856–863. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
249
|
Rahbar K, Afshar-Oromieh A, Seifert R,
Wagner S, Schäfers M, Bögemann M and Weckesser M: Diagnostic
performance of 18F-PSMA-1007 PET/CT in patients with
biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging.
45:2055–2061. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
250
|
Karnes RJ, Choeurng V, Ross AE, Schaeffer
EM, Klein EA, Freedland SJ, Erho N, Yousefi K, Takhar M, Davicioni
E, et al: Validation of a genomic risk classifier to predict
prostate cancer-specific mortality in men with adverse pathologic
features. Eur Urol. 73:168–175. 2018. View Article : Google Scholar
|
|
251
|
Cooperberg MR, Davicioni E, Crisan A,
Jenkins RB, Ghadessi M and Karnes RJ: Combined value of validated
clinical and genomic risk stratification tools for predicting
prostate cancer mortality in a high-risk prostatectomy cohort. Eur
Urol. 67:326–333. 2015. View Article : Google Scholar :
|
|
252
|
Wiegel T, Bartkowiak D, Bottke D, Bronner
C, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A,
et al: Adjuvant radiotherapy versus wait-and-see after radical
prosta-tectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95
trial. Eur Urol. 66:243–250. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
253
|
Li H, Wang Z, Zhang Y, Sun G, Ding B, Yan
L, Liu H, Guan W, Hu Z, Wang S, et al: The immune checkpoint
regulator PDL1 is an independent prognostic biomarker for
biochemical recurrence in prostate cancer patients following
adjuvant hormonal therapy. J Cancer. 10:3102–3111. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
254
|
Van den Broeck T, van den Bergh RCN,
Briers E, Cornford P, Cumberbatch M, Tilki D, De Santis M, Fanti S,
Fossati N, Gillessen S, et al: Biochemical recurrence in prostate
cancer: The European association of urology prostate cancer
guidelines panel recommendations. Eur Urol Focus. Jun 24–2019.Epub
ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
255
|
Tendulkar RD, Agrawal S, Gao T, Efstathiou
JA, Pisansky TM, Michalski JM, Koontz BF, Hamstra DA, Feng FY,
Liauw SL, et al: Contemporary update of a Multi-institutional
predictive nomogram for salvage radiotherapy after radical
prostatectomy. J Clin Oncol. 34:3648–3654. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
256
|
Isharwal S and Stephenson AJ:
Post-prostatectomy radiation therapy for locally recurrent prostate
cancer. Expert Rev Anticancer Ther. 17:1003–1012. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
257
|
Tilki D, Preisser F, Graefen M, Huland H
and Pompe RS: External validation of the European association of
urology biochemical recurrence risk groups to predict metastasis
and mortality after radical prostatectomy in a european cohort. Eur
Urol. 75:896–900. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
258
|
Spratt DE, Dess RT, Zumsteg ZS, Lin DW,
Tran PT, Morgan TM, Antonarakis ES, Nguyen PL, Ryan CJ, Sandler HM,
et al: A systematic review and framework for the use of hormone
therapy with salvage radiation therapy for recurrent prostate
cancer. Eur Urol. 73:156–165. 2018. View Article : Google Scholar
|
|
259
|
Shipley WU, Seiferheld W, Lukka HR, Major
PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman
AL, et al: Radiation with or without antiandrogen therapy in
recurrent prostate cancer. N Engl J Med. 376:417–428. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
260
|
Freedland SJ, Choeurng V, Howard L, De
Hoedt A, du Plessis M, Yousefi K, Lam LL, Buerki C, Ra S, Robbins
B, et al: Utilization of a genomic classifier for prediction of
metastasis following salvage radiation therapy after radical
prostatectomy. Eur Urol. 70:588–596. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
261
|
Semenas J, Allegrucci C, Boorjian SA,
Mongan NP and Persson JL: Overcoming drug resistance and treating
advanced prostate cancer. Curr Drug Targets. 13:1308–1323. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
262
|
Cucchiara V, Cooperberg MR, Dall'Era M,
Lin DW, Montorsi F, Schalken JA and Evans CP: Genomic markers in
prostate cancer decision making. Eur Urol. 73:572–582. 2018.
View Article : Google Scholar
|
|
263
|
Pikor L, Thu K, Vucic E and Lam W: The
detection and implication of genome instability in cancer. Cancer
Metastasis Rev. 32:341–352. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
264
|
Lin X, Ojo D, Wei F, Wong N, Gu Y and Tang
D: A novel aspect of tumorigenesis-BMI1 functions in regulating DNA
damage response. Biomolecules. 5:3396–3415. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
265
|
Lin X, Yan J and Tang D: ERK kinases
modulate the activation of PI3 kinase related kinases (PIKKs) in
DNA damage response. Histol Histopathol. 28:1547–1554.
2013.PubMed/NCBI
|
|
266
|
Wei F, Yan J and Tang D: Extracellular
signal-regulated kinases modulate DNA damage response-a
contributing factor to using MEK inhibitors in cancer therapy. Curr
Med Chem. 18:5476–5482. 2011. View Article : Google Scholar
|
|
267
|
Lucarelli G, Loizzo D, Ferro M, Rutigliano
M, Vartolomei MD, Cantiello F, Buonerba C, Di Lorenzo G,
Terracciano D, De Cobelli O, et al: Metabolomic profiling for the
identification of novel diagnostic markers and therapeutic targets
in prostate cancer: An update. Expert Rev Mol Diagn. 19:377–387.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
268
|
Williams D and Fingleton B: Non-canonical
roles for metabolic enzymes and intermediates in malignant
progression and metastasis. Clin Exp Metastasis. 36:211–224. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
269
|
Priolo C, Pyne S, Rose J, Regan ER, Zadra
G, Photopoulos C, Cacciatore S, Schultz D, Scaglia N, McDunn J, et
al: AKT1 and MYC induce distinctive metabolic fingerprints in human
prostate cancer. Cancer Res. 74:7198–7204. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
270
|
Pettersson A, Gerke T, Penney KL, Lis RT,
Stack EC, Pértega-Gomes N, Zadra G, Tyekucheva S, Giovannucci EL,
Mucci LA and Loda M: MYC overexpression at the protein and mRNA
level and cancer outcomes among men treated with radical
prostatectomy for prostate cancer. Cancer Epidemiol Biomarkers
Prev. 27:201–207. 2018. View Article : Google Scholar :
|
|
271
|
Hammarsten P, Cipriano M, Josefsson A,
Stattin P, Egevad L, Granfors T and Fowler CJ: Phospho-Akt
immunoreactivity in prostate cancer: Relationship to disease
severity and outcome, Ki67 and phosphorylated EGFR expression. PLoS
One. 7:e479942012. View Article : Google Scholar : PubMed/NCBI
|
|
272
|
Flegal KM, Kit BK, Orpana H and Graubard
BI: Association of all-cause mortality with overweight and obesity
using standard body mass index categories: A systematic review and
meta-analysis. JAMA. 309:71–82. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
273
|
Schiffmann J, Karakiewicz PI, Rink M,
Manka L, Salomon G, Tilki D, Budäus L, Pompe R, Leyh-Bannurah SR,
Haese A, et al: Obesity paradox in prostate cancer: Increased body
mass index was associated with decreased risk of metastases after
surgery in 13,667 patients. World J Urol. 36:1067–1072. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
274
|
Bansal D, Undela K, D'Cruz S and Schifano
F: Statin use and risk of prostate cancer: A meta-analysis of
observational studies. PLoS One. 7:e466912012. View Article : Google Scholar : PubMed/NCBI
|
|
275
|
Kollmeier MA, Katz MS, Mak K, Yamada Y,
Feder DJ, Zhang Z, Jia X, Shi W and Zelefsky MJ: Improved
biochemical outcomes with statin use in patients with high-risk
localized prostate cancer treated with radiotherapy. Int J Radiat
Oncol Biol Phys. 79:713–718. 2011. View Article : Google Scholar
|
|
276
|
Song C, Park S, Park J, Shim M, Kim A,
Jeong IG, Hong JH, Kim CS and Ahn H: Statin use after radical
prostatectomy reduces biochemical recurrence in men with prostate
cancer. Prostate. 75:211–217. 2015. View Article : Google Scholar
|
|
277
|
Freedland SJ, Hamilton RJ, Gerber L, Banez
LL, Moreira DM, Andriole GL and Rittmaster RS: Statin use and risk
of prostate cancer and high-grade prostate cancer: Results from the
REDUCE study. Prostate Cancer Prostatic Dis. 16:254–259. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
278
|
Nordström T, Clements M, Karlsson R,
Adolfsson J and Grönberg H: The risk of prostate cancer for men on
aspirin, statin or antidiabetic medications. Eur J Cancer.
51:725–733. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
279
|
Rieken M, Kluth LA, Xylinas E, Seitz C,
Fajkovic H, Karakiewicz PI, Lotan Y, Briganti A, Loidl W, Faison T,
et al: Impact of statin use on biochemical recurrence in patients
treated with radical prosta-tectomy. Prostate Cancer Prostatic Dis.
16:367–371. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
280
|
Pazhanisamy SK: Stem cells, DNA damage,
ageing and cancer. Hematol Oncol Stem Cell Ther. 2:375–384. 2009.
View Article : Google Scholar
|
|
281
|
Vitale I, Manic G, De Maria R, Kroemer G
and Galluzzi L: DNA damage in stem cells. Mol Cell. 66:306–319.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
282
|
Siddique HR and Saleem M: Role of BMI1, a
stem cell factor, in cancer recurrence and chemoresistance:
Preclinical and clinical evidences. Stem Cells. 30:372–378. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
283
|
Lin X, Gu Y and Tang D: BMI1, ATM and DDR.
Oncoscience. 2:665–666. 2015.PubMed/NCBI
|
|
284
|
Lin X, Wei F, Whyte P and Tang D: BMI1
reduces ATR activation and signalling caused by hydroxyurea.
Oncotarget. 8:89707–89721. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
285
|
Wei F, Ojo D, Lin X, Wong N, He L, Yan J,
Xu S, Major P and Tang D: BMI1 attenuates etoposide-induced G2/M
checkpoints via reducing ATM activation. Oncogene. 34:3063–3075.
2015. View Article : Google Scholar
|
|
286
|
Wei L, Wang J, Lampert E, Schlanger S,
DePriest AD, Hu Q, Gomez EC, Murakam M, Glenn ST, Conroy J, et al:
Intratumoral and intertumoral genomic heterogeneity of multifocal
localized prostate cancer impacts molecular classifications and
genomic prognosticators. Eur Urol. 71:183–192. 2017. View Article : Google Scholar
|
